Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 in Idiopathic CD4 T Cell Lymphocytopenia
NCT03519464Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2019
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2019; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03519464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519464.